Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Assets: 2015-2025

Historic Assets for Intellia Therapeutics (NTLA) over the last 10 years, with Sep 2025 value amounting to $925.3 million.

  • Intellia Therapeutics' Assets fell 21.14% to $925.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $925.3 million, marking a year-over-year decrease of 21.14%. This contributed to the annual value of $1.2 billion for FY2024, which is 8.45% down from last year.
  • Intellia Therapeutics' Assets amounted to $925.3 million in Q3 2025, which was up 2.93% from $898.9 million recorded in Q2 2025.
  • Intellia Therapeutics' 5-year Assets high stood at $1.5 billion for Q4 2022, and its period low was $672.2 million during Q2 2021.
  • For the 3-year period, Intellia Therapeutics' Assets averaged around $1.2 billion, with its median value being $1.2 billion (2024).
  • Per our database at Business Quant, Intellia Therapeutics' Assets soared by 191.12% in 2021 and then fell by 24.56% in 2025.
  • Intellia Therapeutics' Assets (Quarterly) stood at $1.3 billion in 2021, then rose by 17.43% to $1.5 billion in 2022, then decreased by 14.42% to $1.3 billion in 2023, then declined by 8.45% to $1.2 billion in 2024, then dropped by 21.14% to $925.3 million in 2025.
  • Its Assets was $925.3 million in Q3 2025, compared to $898.9 million in Q2 2025 and $986.2 million in Q1 2025.